BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 17645711)

  • 1. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens.
    Anderson RD; Chinnakotla S; Guo L; Perrillo RP; Klintmalm GB; Davis GL
    Clin Transplant; 2007; 21(4):510-7. PubMed ID: 17645711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.
    Hooman N; Rifai K; Hadem J; Vaske B; Philipp G; Priess A; Klempnauer J; Tillmann HL; Manns MP; Rosenau J
    Liver Transpl; 2008 Apr; 14(4):435-42. PubMed ID: 18383078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
    Marzano A; Marengo A; Andreone P; Volpes R; Canova D; Cursaro C; Riili A; Fiorentino B; Bacci M; Guazzini S; Burra P
    Minerva Med; 2010 Dec; 101(6):373-83. PubMed ID: 21196896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Ferretti G; Merli M; Ginanni Corradini S; Callejon V; Tanzilli P; Masini A; Ferretti S; Iappelli M; Rossi M; Rivanera D; Lilli D; Mancini C; Attili A; Berloco P
    Transplant Proc; 2004 Apr; 36(3):535-8. PubMed ID: 15110584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis.
    Beckebaum S; Herzer K; Bauhofer A; Gelson W; De Simone P; de Man R; Engelmann C; Müllhaupt B; Vionnet J; Salizzoni M; Volpes R; Ercolani G; De Carlis L; Angeli P; Burra P; Dufour JF; Rossi M; Cillo U; Neumann U; Fischer L; Niemann G; Toti L; Tisone G
    Ann Transplant; 2018 Nov; 23():789-801. PubMed ID: 30420590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
    Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
    Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
    Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
    Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B prophylaxis in living donor liver transplantation: single center experience.
    Yaprak O; Dayangac M; Balci D; Bas K; Yuzer Y; Tokat Y
    Hepatogastroenterology; 2010; 57(102-103):1178-82. PubMed ID: 21410054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin treatment].
    Jiao ZY; Yan LN; Li B; Zeng Y; Wen TF; Lu SC; Zhao JC; Wang WT; Xu MQ; Yang JY; Li ZH; Ma YK; Zhang ZW; Chen ZY
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):804-8. PubMed ID: 18073060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.